Canaccord Genuity Maintains Buy Rating on Clover Health Investments (CLOV) with Lowered Price Target to $4.10.

Canaccord Genuity has maintained a "Buy" rating on Clover Health Investments (CLOV) but lowered the price target from $4.50 to $4.10. The analyst adjustment reflects an 8.89% decrease. UBS also maintained a "Neutral" rating with a lowered price target of $3.00, a 33.33% change. The average one-year price target for CLOV is $3.52, with an estimated upside of 59.28% from the current price of $2.21.

Canaccord Genuity has maintained a "Buy" rating on Clover Health Investments (CLOV) but lowered the price target from $4.50 to $4.10. The analyst adjustment reflects an 8.89% decrease. UBS also maintained a "Neutral" rating with a lowered price target of $3.00, a 33.33% change. The average one-year price target for CLOV is $3.52, with an estimated upside of 59.28% from the current price of $2.21 [1].

Analysts' opinions on CLOV have been mixed, with some maintaining a "Buy" rating while others have adjusted their price targets. Canaccord Genuity's recent adjustment reflects a more cautious outlook, potentially due to recent market volatility or changes in the company's financial projections. Meanwhile, UBS's "Neutral" rating suggests a more neutral stance on the stock's prospects.

Investors should closely monitor these adjustments and the upcoming earnings reports for CLOV, which are scheduled for Tuesday after the market close. The earnings announcement will provide more clarity on the company's financial health and could influence its stock price.

References:

[1] https://www.marketbeat.com/stocks/NASDAQ/CLOV/forecast/